Ddeepull
Deepull is a Barcelona-based diagnostics company developing UllCORE, a fully automated molecular testing system that detects sepsis-causing pathogens and antibiotic resistance markers directly from whole blood in about an hour, without the need for blood culture. The company received FDA Breakthrough Device Designation in December 2024 and is a Series C-stage medtech scaleup founded by the team behind STAT-Dx (sold to QIAGEN in 2018).
SectorsDiagnostics, Medical Devices, Molecular Testing, Sepsis/Infectious Disease
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Founders
J
Jordi Carrera
Co-Founder & CEO
R
Rafel Bru Gibert
Co-Founder & CTO
Global models 5
KKarius
United States · kariusdx.com ↗
Finds pathogens behind sepsis and other serious infections directly from a blood sample, with no culture step, and sells the test to hospitals.
~$270MComparable
IInflammatix
United States · inflammatix.com ↗
Rapid sepsis diagnosis from whole blood on its own automated instrument and cartridge system sold to hospital emergency departments, though it reads the patient's immune response rather than detecting pathogens.
~$200MComparable
T
T2 Biosystems
United States · www.t2biosystems.com ↗
Automated instrument and cartridges that detect sepsis pathogens and resistance genes directly from whole blood in a few hours, without blood culture.
~$100M (pre-IPO VC)Comparable
SSelux Diagnostics
United States · seluxdx.com ↗
Automated hospital system that speeds up bloodstream infection diagnosis and antibiotic-resistance profiling for sepsis patients, sold as instrument plus consumables.
~$100M+Comparable
DDay Zero Diagnostics
United States · www.dayzerodiagnostics.com ↗
Sequencing-based test that identifies bloodstream pathogens and their antibiotic resistance directly from blood, without culture, for faster sepsis treatment.
~$50MComparable
In the same niche 48 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 16
Open as list →
AAlta Life Sciences
www.altals.com
AAsabys Partners
asabys.com
CColumbus Venture Partners
columbusvp.com
EEuropean Investment Bank
www.eib.org
A
AXIS
www.axispart.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
WWe Venture Capital
weventurecapital.com
KKurma Partners
MMérieux Equity Partners
P
Panakès Partners
UUI Investissement
AAliath Bioventures
CCGHealth Ventures
G
Gesamo
SSofimac Innovation (Pertinence Invest 2)
WWerfen
Funding rounds 4
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-04-29 | Series C | €50M |
Columbus Venture Partners, Panakès Partners, Mérieux Equity Partners
+9 more
|
| 2023-03-01 | Series B | €17M |
Sabadell Asabys (Asabys Partners)
+6 more
|
| 2022-12-13 | Venture Debt | €20M | European Investment Bank |
| 2020-07-07 | Series A | €3.5M |
Alta Life Sciences, Kurma Partners
+2 more
|
News 6
Open as list →| Published | Article |
|---|---|
| 2026-05-07 |
Healthtech: 10 companies that raised the most in 2025 ↗
Tech.eu
2026-05-07 |
| 2026-02-19 |
Catalonia hits record investment in health startups and scaleups and consolidates BioRegion as leading European hub for research and industry ↗
Biocat
2026-02-19 |
| 2025-04-29 |
deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection ↗
GlobeNewswire
2025-04-29 |
| 2025-04-29 |
deepull raises $57m in Series C funds for advancing pathogen detection system ↗
Medical Device Network
2025-04-29 |
| 2024-12-02 |
FDA grants breakthrough device designation to deepull's BSI test ↗
Medical Device Network
2024-12-02 |
| 2024-04-25 |
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 ↗
GlobeNewswire
2024-04-25 |